Male Hypogonadism Market Overview:
Global Male Hypogonadism Market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, supported by a CAGR of 3.1% during the forecast period. Male hypogonadism is a medical condition in which testes cannot produce enough testosterone, resulting in decreased development of muscle mass, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.
The market growth is driven by factors such as increase in incidence of hypogonadism, rise in awareness about hypogonadism & its treatment option, and growth in infertility rates. In addition, the prevalence of hypogonadism is high in the geriatric population, and patient population with diabetes & obesity. Thus, growth in such population and rise in incidence & prevalence of chronic diseases such as diabetes & obesity are expected to boost the market growth. According to various studies, men aged between 60 and 80 years have low testosterone levels by 20% and 80%, respectively, than normal testosterone levels for young men. Men above 60 years have the highest prevalence of hypogonadism. Countries such as Japan, China, U.S. and others, with surging geriatric population, witness high demand for therapies used to treat male hypogonadism.
Percentage of Total Population Aged 65 Years & Above by Country
Cautions & warnings issued by the FDA against side effects of TRT products is expected to restrain the market growth during the forecast period. However, novel treatment options are under development, which show positive results in terms of efficacy and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to create new opportunities during the analysis period.
Male Hypogonadism Market Segmentation
Testosterone replacement therapy (TRT) held the largest share in 2015, accounting for more than half of the market; however, this segment is expected to witness decreasing growth rate, owing to post application side effects such as various cardiovascular diseases, blood clots, and stroke. Gonadotropin and gonadotropin-releasing hormones segment is expected to grow at the highest CAGR during the forecast period, owing to rise in adoption of this therapy with surging prevalence hypogonadal men. By drug delivery method, injectables held nearly half of the market share of the total in 2015. By type, pituitary disorders segment was the largest revenue contributor in 2015.
Geographically, North America held the largest market share (more than three-fourths share) in 2015, and it is anticipated to continue its dominance during the forecast period. Increase in population with hypogonadism owing to rise in in obesity, co-morbidities such as diabetes, and poor health in the geriatric population drive the North American market growth. Mexico is expected to grow at the significant CAGR of 6.7% in North America.
Mexico Male Hypogonadism Market Revenue, 2014-2022 ($Million)
Asia-Pacific is estimated to register the highest growth rate in the coming years. This region is densely populated, with India and China being the most populated countries, accounting for major share of the patient population with diabetes & obesity. Japan, China, and others possess the highest aging population; therefore, the prevalence of male hypogonadism is high in these countries. This market growth is supplemented by the increase in men population suffering from infertility. For instance, according to Andrology Australia, androgen deficiency is common and affects 1 in 200 men under 60 years of age. As per the Australian Family Physician Medical Journal, the prevalence of hypogonadism may be up to 12% in men older than 40 years of age. In addition, the increase in healthcare reforms and rise in awareness among people are expected to boost the market growth.
Comprehensive competitive analysis and profiles of major market players, such as AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli Lilly and Company Ltd., Endo International plc, Merck & Co., Inc., Ferring, Finox Biotech, IBSA Institut Biochimque SA, Laboratoires Genevrier, and Teva Pharmaceutical Industries Ltd., are provided in the report.
Male Hypogonadism Market Key Benefits
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis by therapy helps in understanding the various types of therapies used to treat hypogonadism.
- Comprehensive analysis of all geographical regions is provided, which assist in determining the main opportunities in these geographies.
- Key players within the market are profiled and their strategies are analyzed thoroughly to determine the competitive outlook of the global market.
Male Hypogonadism Market Key Segmentation:
- Testosterone Replacement Therapy
- Gonadotropin and Gonadotropin-Releasing Hormones Therapy
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- Human Chorionic Gonadotropin (hCG)
- Gonadotropin-Releasing Hormone (GnRH)
By Drug Delivery
- Topical Gels
- Transdermal Patches
- Klinefelter's Syndrome
- Kallmann Syndrome
- Pituitary Disorders
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Middle East
List of Key Players Profiled in the Report
- AbbVie Inc.
- Allergan plc
- Astrazeneca plc
- Bayer AG
- Eli Lilly and Company Ltd.
- Endo International plc.
- Merck & Co., Inc.
- Finox Biotech,
- IBSA Institut Biochimque SA
- Laboratoires Genevrier
- Teva Pharmaceutical Industries Ltd.
List of other Players in the Value Chain (These players are not profiled in the report. The same will be included on request.)
- Lipocine Inc.
- Pfizer Inc.
- Aytu Biosciences
- Diurnal Group PLC
- Hyundai Pharmaceuticals Co Ltd.
- Perrigo Company plc
- Novus Biologicals, LLC